ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

244
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
bearishLupin Ltd
09 Sep 2022 20:32

Lupin Ltd (LPC IN): Muted Q1FY23 Results as The US Sales Dipped Significantly

Lupin’s US business dipped significantly in Q1, due to price erosion, paring down inventories to normalized levels, and product rationalization....

Logo
442 Views
Share
02 Sep 2022 07:05

NIFTY NEXT50 Index Rebalance: Significant Impact for an Overlooked Index

There are 7 adds/deletes for the NIFTY NEXT50 Index. The adds have outperformed the deletes but there are significant days of delivery volume to...

Logo
682 Views
Share
21 Jul 2022 10:20

NIFTY100 Index Rebalance Preview: Couple of Changes in August, Then 5 More in September

There are two index changes at the close on 5 August, then there should be 5 more at the close on 29 September. Passive funds will have over 4-5...

Logo
662 Views
Share
12 Jul 2022 10:08

NIFTY100 & CPSE Index Rebalance: Some Big Changes in 3 Weeks

LIC and Tata Power will be added to the NIFTY100 Index at the close on 5 August. NMDC is being deleted from the NIFTY100 & CPSE indices. There is a...

Logo
659 Views
Share
bullishLupin Ltd
23 May 2022 08:41Broker

Lupin - Disappointing Quarter; Focus on Driving Cost Efficiencies

We maintain our Buy rating on Lupin, but lower our estimates to account for lower US sales and cost pressures. EBITDA margin came in at 7% for the...

Logo
343 Views
Share
x